{"nctId":"NCT05568615","briefTitle":"Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS","startDateStruct":{"date":"2022-10-26","type":"ACTUAL"},"conditions":["ALS"],"count":15,"armGroups":[{"label":"MT-1186 orally","type":"EXPERIMENTAL","interventionNames":["Drug: MT-1186"]}],"interventions":[{"name":"MT-1186","otherNames":["Edaravone"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must provide a signed and dated informed consent form (ICF) to participate in the study.\n* Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study\n* Subjects must be willing to cooperate and comply with all protocol restrictions and requirements.\n* Subjects who successfully complete Week 96 of Study MT-1186-A03 or Week 48 of Study MT-1186-A04 and have been compliant with study drug (80-120%).\n\nExclusion Criteria:\n\n* Subjects of childbearing potential unwilling to use a highly effective method of contraception from the Visit #1 until 3 months after the last dose of study medication.\n* Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS at Week 96 of the A03 study or at Week 48 of the A04 study.\n* Subjects who are not eligible to continue in the study, as judged by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With AEs and Adverse Drug Reactions","description":"Adverse Event (AE) is classified as treatment emergent if it newly occurred after the first dose of investigational product or if a pre-dose event increases in severity following the first dose of investigational product.\n\nAdverse Drug Reaction (ADR) is a noxious and unintended response to a medicinal product that occurs at doses normally used for prophylaxis, diagnosis, or therapy of disease.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"ALSFRS-R Total Score","description":"The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation (â‰¥23 Hours/Day)","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":15},"commonTop":["Otitis externa","Tinea cruris","Constipation","Eczema","Decubitus ulcer"]}}}